⌘K

07:07:35·14d

SECFiling

C4 Therapeutics Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

CCCC· C4 Therapeutics Inc.

Health Care

Original source

Companies

CCCC
C4 Therapeutics Inc.
Health Care

Recent analyst ratings

Dec 2UpdateTD Cowen-
Sep 17UpdateBarclays$8.00
Sep 15UpdateStephens$6.00
Sep 4UpdateGuggenheim$8.00
Dec 19UpdateWells Fargo$12.00
Nov 18UpdateStephens$4.00

Related

SEC1d
Amendment: SEC Form SCHEDULE 13G/A filed by C4 Therapeutics Inc.
SEC13d
C4 Therapeutics Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
PR14d
C4 Therapeutics Expands Long-Term Partnership with Roche Through New Collaboration Agreement Focused on Discovering and Developing Degrader-Antibody Conjugates (DACs)
INSIDER20d
SEC Form 4 filed by Anderson Kenneth Carl
INSIDER20d
SEC Form 4 filed by Grogan Donna Roy
PR29d
C4 Therapeutics Announces First Patient Dosed in Phase 1b Trial of Cemsidomide in Combination with Elranatamab (ELREXFIO®) for Relapsed/Refractory Multiple Myeloma
PR45d
C4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
PR49d
Next-Generation Cancer Therapies Post Breakthrough Results Across Multiple Tumor Types